Medwave, Inc. (Nasdaq: MDWV), the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today on the heels of the launch of its new Primo(TM) brand, that it has retained the services of ASI Marketing, a full-service marketing communications firm, to coordinate and execute branding, public and media relations initiatives. This is the first time Medwave has partnered with an agency; a move designed to fortify the Medwave brand in the consciousness of target audiences, while assuring a highly publicized launch of the Primo(TM) monitoring system.
"With this partnership, we are taking our marketing efforts to the next level," said Medwave President and CEO Tim O'Malley. "Their industry expertise and knowledgeable, results-driven team will help assure a successful launch of the Primo brand, while providing strong branding support for Medwave as a company."
ASI Marketing is known for its success building strong brands in the healthcare, med-tech and pharmaceutical industries, having worked with Blue Cross/Blue Shield, Bristol-Myers-Squibb, Guidant, Medtronic, Merck, Miracle- Ear and Pfizer.
"We are particularly enthusiastic about the opportunity to work with the Medwave brand," said Will Sullivan, ASI Marketing President. "They have a unique vision, and their products have the potential to change the industry landscape. In fact, we've agreed to accept some payment in the form of stock options. This proves how confident we are in their technology -- and in our abilities."
As a full-service firm, ASI Marketing will handle advertising, public and media relations, copywriting, graphic / interactive design, and general strategic marketing counsel for Medwave.
"Medwave is an innovative company and Primo is an innovative brand," added O'Malley. "It stands to reason we should work with an innovative marketing company, and ASI Marketing fits the bill."
About ASI Marketing
Located in Minneapolis, MN, ASI Marketing ( http://www.asimarketing.com ) is a full-service marketing communications firm that provides clients with senior-level expertise in marketing, public relations, media relations, public affairs and reputation management services, as well as creative and interactive solutions. For more than 25 years, ASI Marketing has delivered results for its clients by providing thoughtful, creative, and financially sound marketing communications services.
Medwave, Inc. develops, manufactures, and distributes sensor-based non- invasive blood pressure solutions. Its Vasotrac(R) APM205A NIBP Monitor, the Vasotrac(R) APM205A Model DS, and the MJ23 OEM Module are new approaches to non-invasive blood pressure monitoring. Medwave's Legato(TM) OEM Developers Kit is designed to introduce the innovative Vasotrac(R) technology to OEM designers. The Primo(TM) Non-Invasive Blood Pressure Monitoring System, Medwave's latest innovation, is designed to be sold into the point of care blood pressure monitoring market, estimated to be in the $600 million per year range. Medwave has received the necessary regulatory clearances to market its technology in Europe, Asia, and the United States. Medwave's technology is installed in over 500 hospitals and clinics worldwide. Medwave has received the Seal of Acceptance from the Alliance of Children's Hospitals, as well as the Frost & Sullivan Market Engineering Award for Technology Innovation and the Frost & Sullivan Customer Value Enhancement Award. Medwave currently has supply and/or other agreements with Nihon Kohden, Zoll Medical Corporation, Analogic Corporation, and a global electronics company. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time, including the company's estimates of cost savings related to use of Primo, are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in the Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward- looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), and Primo(TM) are trademarks of Medwave, Inc.